Candel Therapeutics Appoints Dr. Carl H. June to Research Advisory Board
Candel Therapeutics, Inc. (NASDAQ: CADL) has made a significant stride in cancer immunotherapy by appointing Dr. Carl H. June to its Research Advisory Board (RAB). Based in Needham, Massachusetts, Candel is dedicated to developing innovative biological immunotherapies aimed at combating cancer more effectively. Dr. June, a luminary in the field of cancer research, is recognized for creating the first FDA-approved CAR-T cell therapy, illustrating his wealth of knowledge and experience in harnessing the immune system to fight cancer.
Dr. June's Vision for Immunotherapy
Diving into his role, Dr. June expressed his enthusiasm by saying, "I'm pleased to join Candel’s Research Advisory Board at such a pivotal time for the Company. Candel's innovative approach to viral immunotherapy aligns with my passion for harnessing the power of the immune system to fight cancer." He is eager to support the advancement of promising therapies, highlighting their potential to aid patients facing various types of cancer.
Dr. June's Impressive Background
Currently, Dr. June holds the title of Richard W. Vague Professor in Immunotherapy at the University of Pennsylvania's Perelman School of Medicine, where he leads the Center for Cellular Immunotherapies and the Parker Institute for Cancer Immunotherapy. His work extensively covers lymphocyte activation mechanisms related to both immune tolerance and adoptive immunotherapy aimed at treating cancer and chronic infections.
Impact on Candel's Research Initiatives
Dr. Paul Peter Tak, President and CEO of Candel, commented on this appointment, stating, "We are excited to expand our Research Advisory Board with the addition of Dr. June. His distinguished expertise in T cell engineering and immunology will provide invaluable resources as we advance CAN-2409 across multiple solid tumor indications. We anticipate submitting a Biologics License Application (BLA) for prostate cancer in the near future." This submission reflects the company’s commitment to pushing the boundaries of current cancer treatments.
About Candel Therapeutics
Candel Therapeutics is at the forefront of cancer treatment, focusing on developing off-the-shelf viral immunotherapies. These therapies are designed to trigger a tailored, systemic anti-tumor immune response, empowering patients in their fight against cancer. The company has developed two main clinical-stage platforms based on genetically modified adenovirus and herpes simplex virus (HSV) gene constructs. The lead candidate from the adenovirus platform, CAN-2409, is set to play a key role in their therapeutic arsenal.
Innovative Cancer Treatment Platforms
Candel’s recent accomplishments include the successful completion of phase 2a clinical trials of CAN-2409 in cancers such as non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC). Furthermore, a pivotal phase 3 clinical trial of CAN-2409 in localized prostate cancer was conducted under a Special Protocol Assessment (SPA) with the FDA. The FDA has awarded Fast Track Designation for CAN-2409 combined with prodrug (valacyclovir), strategically targeting resistant cases of NSCLC and localized prostate cancer alongside radiation treatment.
Future Prospects and Clinical Trials
Another notable candidate, CAN-3110, which originates from the HSV platform, is currently undergoing a phase 1b clinical trial for recurrent high-grade glioma. Initial findings from this research have been published in a reputable scientific journal, signaling the candidate's potential. The FDA has granted CAN-3110 both Fast Track Designation and Orphan Drug Designation, recognizing its potential in treating serious conditions.
Introducing enLIGHTEN™ Discovery Platform
Candel's enLIGHTEN™ Discovery Platform enhances their research capabilities by utilizing a systematic, iterative approach that leverages human biology and sophisticated analytical methods. This innovative platform aims to develop new viral immunotherapies particularly targeted at solid tumors.
Frequently Asked Questions
What is the significance of Dr. June's appointment?
Dr. June's expertise in immunotherapy will greatly enhance Candel's research initiatives, particularly in developing new cancer treatments.
What therapies is Candel currently developing?
Candel is focusing on CAN-2409 for solid tumors and CAN-3110 for recurrent high-grade glioma, among others.
What designations has CAN-2409 received from the FDA?
CAN-2409 has received Fast Track Designation, Regenerative Medicine Advanced Therapy (RMAT) Designation, and Orphan Drug Designation for various indications.
What is the importance of the enLIGHTEN™ Discovery Platform?
This platform strengthens Candel’s ability to create novel viral immunotherapies that could treat challenging solid tumors.
How can I learn more about Candel Therapeutics?
For more information about their innovative approaches and pipeline, please visit www.candeltx.com.
